← Back to Search

NMDA receptor antagonist

Sublingual Micro-Dose Ketamine for Acute Stress Disorder

Phase 4
Waitlist Available
Led By Andre Atoian, MD
Research Sponsored by Limbic Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 120 days
Awards & highlights

Study Summary

A retrospective chart review of an open-label trial of low-dose ketamine administered to front-line Healthcare workers who were identified as experiencing acute stress disorder due to the COVID-19 Pandemic.

Eligible Conditions
  • Acute Stress Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 120 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 120 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patient self-reported outcome measure

Trial Design

1Treatment groups
Experimental Treatment
Group I: Sublingual Micro-Dose KetamineExperimental Treatment1 Intervention
Ketamine micro-dose 37.5mg compounded sublingual daily administration

Find a Location

Who is running the clinical trial?

Enovex PharmacyUNKNOWN
Limbic MedicalLead Sponsor
Andre Atoian, MDPrincipal InvestigatorLimbic Medical

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Apr 2025